Trial Profile

Mucopolysaccharidosis VII Disease Monitoring Program (MPS VII DMP)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 22 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vestronidase alfa (Primary)
Indications Mucopolysaccharidosis VII
Focus Adverse reactions; Therapeutic Use
Acronyms MPS VII DMP
Sponsors Ultragenyx Pharmaceutical

Most Recent Events

11 Jun 2026 Planned End Date changed from 1 May 2033 to 1 Apr 2032.
11 Jun 2026 Planned primary completion date changed from 1 May 2033 to 1 Apr 2032.
10 Oct 2022 Planned number of patients changed from 35 to 50.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com